Galapagos Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

March 31, 2025

Galapagos (AMS:GLPG) Full Year 2024 Results

Key Financial Results

Revenue: €275.6m (up 15% from FY 2023).
Net loss: €1.28m (loss narrowed by 68% from FY 2023).
€0.019 loss per share (improved from €0.061 loss in FY 2023).

GLPG Products In Clinical Trials

Phase I: 1.
Phase II: 8.

revenue-and-expenses-breakdown — ENXTAM:GLPG Revenue and Expenses Breakdown March 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Galapagos EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) exceeded analyst estimates.

The primary driver behind last 12 months revenue was the United States of America segment contributing a total revenue of €240.8m (87% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to €335.5m (78% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of €185.8m. Explore how GLPG's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe.

Performance of the market in the Netherlands.

The company's shares are down 2.2% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Galapagos that you need to take into consideration.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.